NICE recommendation expands patient eligibility for AbbVie’s Ozurdex
Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status
Read More
Tag: Ozurdex
Final NHS nod for Allergan’s Ozurdex, AbbVie’s Humira in uveitis
Cost regulators for NHS treatments in England and Wales have deemed AbbVie’s Humira and Allergan’s Ozurdex clinically and cost effective for treating adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids.
Read More
NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis
Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
